Ioxilan

Ioxilan

Clinical data
Trade names	Oxilan
AHFS/Drugs.com	FDA Professional Drug Information
Routes of administration	intravenously
ATC code	V08AB12 (WHO)
Legal status
Legal status	US: ℞-only Discontinued
Pharmacokinetic data
Bioavailability	N/A
Protein binding	negligible
Metabolism	none
Elimination half-life	2 hours
Excretion	Mostly renal
Identifiers
IUPAC name 1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number	107793-72-6 N
PubChem CID	3743
DrugBank	DB09135 Y
ChemSpider	3612 Y
UNII	A4YJ7J11TG
KEGG	D02161 Y
ChEMBL	ChEMBL1201075 N
CompTox Dashboard (EPA)	DTXSID0048717
Chemical and physical data
Formula	C18H24I3N3O8
Molar mass	791.112 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C
InChI InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) Y Key:UUMLTINZBQPNGF-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but has been discontinued in 2017.

Mechanism of action

Ioxilan is an iodinated contrast agent.